Overview

Niclosamide In Moderate COVID-19

Status:
Not yet recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.

Phase:

Phase 2

Details

Lead Sponsor:

First Wave Bio, Inc.

Treatments:

Niclosamide